Symptomatic Pneumonitis with Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small-Cell Lung Cancer - JTO Clinical and Research Reports https://t.co/MZ4Ogjxvbp
Con una diferencia en recurr local a 10 añ entre Rt (0.9) vs no Rt (9,5),sin alcanzarse el plateau, con lo q conlleva una recaída en términos emocionales, posible mayor agresividad del tumor y peor coste eficiencia, la RT sigue teniendo plena indicación en este escenario
@GeneticaCancer ha participado en el Young Spanish Molecular Imaging Network meeting Day! del European Society for Molecular Imaging
@lopplez presentó su herramienta bioinformática diseñada para la investigación ómica utilizando imágenes de tomografía computarizada de pulmón🧬🧪
From all analyzed SNPs, only 12 have great potential as esophagitis genetic risk factors and deserve further exploration. This review highlights the efforts that have been made to date in the radiogenomic study of radiotoxicity in lung cancer.
https://t.co/2oVoppbrll
What have we learned so far from radiogenomics in #lungcancer ?
We have published a review of association studies between genetic variants and radiotherapy-induced adverse effects in #lungcancer patients.
Radiogenomics in lung cancer: Where are we?
The methodologies and endpoints vary greatly between studies; analyzing SNPs from the candidate gene approach, together with the study in cohorts limited by the sample size, has complicated the possibility of having validated results.
The most studied SNPs are located in genes related to DNA double-strand repair pathways, inflammation, and in pathways related to the immune system or apoptosis.
Our group @GeneticaCancer [@idis_research and @GMXenomica] participated in a new work in collaboration with @RequiteProject
Comparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study https://t.co/gKhcSK60Zx
Esta semana, compañeros bioinformáticos defienden nuestra investigación en el Symposium on Cancer genomics and epitranscriptomics: from the bench to the clinic👏
November 30th to December 2nd 2022 (Salamanca, Spain)
Organizado por el Centro de Investigación del Cáncer (CIC)
Our last @GeneticaCancer paper in collaboration with @RequiteProject
High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer https://t.co/zfEVSUoXNY
Ángel Carracedo: “En 2027 haberá tratamento para 1.000 enfermidades raras”
O investigador galego analiza a situación e o futuro da medicina personalizada nun encontro celebrado en Santiago de Compostela https://t.co/9hLFGI9TRE
@GeneticaCancer in collaboration with @RequiteProject published:
correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in NSCLC @lungcancer patients: Results of the REQUITE study https://t.co/GzxbVXNvfH
@GeneticaCancer in collaboration with @RequiteProject published:
correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in NSCLC @lungcancer patients: Results of the REQUITE study https://t.co/GzxbVXNvfH
One of our last collaborations [@GeneticaCancer ] with The Radiogenomics Consortium:
Meta-GWAS identifies the heritability of acute radiation-induced toxicities in head and neck cancer - Radiotherapy and Oncology https://t.co/XAUQUmlFAh